$CING
Cingulate Inc.

2023 Q2 Form 10-Q Financial Statement

#000149315223016183 Filed on May 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.906M $1.721M $2.247M
YoY Change 1.92% -23.39% 192.72%
% of Gross Profit
Research & Development $4.456M $2.129M $2.762M
YoY Change 104.57% -22.94% 391.05%
% of Gross Profit
Depreciation & Amortization $155.3K $100.6K $101.4K
YoY Change 53.11% -0.79% -41.94%
% of Gross Profit
Operating Expenses $4.456M $2.129M $5.009M
YoY Change 104.57% -57.51% 276.6%
Operating Profit -$6.362M -$3.850M -$5.009M
YoY Change 57.14% -23.14%
Interest Expense $252.5K $187.5K $5.830K
YoY Change 2916.73% 3116.12% -255.05%
% of Operating Profit
Other Income/Expense, Net -$253.9K -$154.9K $5.833K
YoY Change -3133.93% -2755.44%
Pretax Income -$6.616M -$4.005M -$5.004M
YoY Change 63.75% -19.96% 275.1%
Income Tax
% Of Pretax Income
Net Earnings -$6.616M -$4.005M -$5.004M
YoY Change 63.75% -19.96% 275.1%
Net Earnings / Revenue
Basic Earnings Per Share -$0.57 -$0.35 -$0.44
Diluted Earnings Per Share -$0.57 -$0.35 -$442.4K
COMMON SHARES
Basic Shares Outstanding 11.70M shares 11.31M shares 11.31M shares
Diluted Shares Outstanding 11.69M shares 565.5K shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $349.8K $1.739M $12.62M
YoY Change -95.73% -86.22%
Cash & Equivalents $349.8K $1.739M $12.61M
Short-Term Investments $930.00
Other Short-Term Assets $1.653M $1.983M $1.307M
YoY Change -6.44% 51.68%
Inventory
Prepaid Expenses $1.653M $1.983M
Receivables $35.47K $31.95K $651.4K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $2.038M $3.753M $14.57M
YoY Change -79.83% -74.25%
LONG-TERM ASSETS
Property, Plant & Equipment $2.686M $2.841M $3.859M
YoY Change -9.04% -26.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $3.190M $3.410M $3.859M
YoY Change -13.83% -11.65%
TOTAL ASSETS
Total Short-Term Assets $2.038M $3.753M $14.57M
Total Long-Term Assets $3.190M $3.410M $3.859M
Total Assets $5.227M $7.163M $18.43M
YoY Change -62.13% -61.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.612M $599.0K $556.3K
YoY Change 471.17% 7.68%
Accrued Expenses $1.018M $699.2K $1.059M
YoY Change 226.82% -34.0%
Deferred Revenue
YoY Change
Short-Term Debt $8.000M $5.000M $0.00
YoY Change
Long-Term Debt Due $15.92K $16.30K $15.34K
YoY Change 2.25% 6.26%
Total Short-Term Liabilities $10.99M $6.659M $1.631M
YoY Change 1090.56% 308.26%
LONG-TERM LIABILITIES
Long-Term Debt $13.72K $17.32K $33.61K
YoY Change -53.7% -48.47%
Other Long-Term Liabilities $317.3K $405.5K $749.5K
YoY Change -52.34% -45.9%
Total Long-Term Liabilities $331.1K $422.8K $783.1K
YoY Change -52.4% -46.01%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.99M $6.659M $1.631M
Total Long-Term Liabilities $331.1K $422.8K $783.1K
Total Liabilities $11.33M $7.081M $2.414M
YoY Change 599.57% 193.34%
SHAREHOLDERS EQUITY
Retained Earnings -$80.03M -$73.41M
YoY Change 31.68%
Common Stock $1.206K $1.131K
YoY Change 6.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.099M $81.61K $16.02M
YoY Change
Total Liabilities & Shareholders Equity $5.227M $7.163M $18.43M
YoY Change -62.13% -61.14%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$6.616M -$4.005M -$5.004M
YoY Change 63.75% -19.96% 275.1%
Depreciation, Depletion And Amortization $155.3K $100.6K $101.4K
YoY Change 53.11% -0.79% -41.94%
Cash From Operating Activities -$4.604M -$3.576M -$3.864M
YoY Change 4.34% -7.45% 130.85%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $37.14K -$10.40K
YoY Change -457.07% -84.35%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 -$37.14K -$10.40K
YoY Change -100.0% 257.07% -84.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.215M -$3.920K -3.680K
YoY Change -85828.53% 6.52% -100.27%
NET CHANGE
Cash From Operating Activities -4.604M -$3.576M -3.864M
Cash From Investing Activities 0.000 -$37.14K -10.40K
Cash From Financing Activities 3.215M -$3.920K -3.680K
Net Change In Cash -1.389M -$3.618M -3.879M
YoY Change -68.57% -6.73% 895.96%
FREE CASH FLOW
Cash From Operating Activities -$4.604M -$3.576M -$3.864M
Capital Expenditures $0.00 $37.14K -$10.40K
Free Cash Flow -$4.604M -$3.614M -$3.854M
YoY Change 4.34% -6.24% 139.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
usd
CY2022Q1 us-gaap Depreciation
Depreciation
101429 usd
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001862150
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
usd
CY2023Q1 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
usd
CY2022Q1 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
usd
CY2023Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
usd
CY2022Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
usd
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q1 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-40874
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Cingulate Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-3825535
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1901 W. 47th Place
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Kansas City
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
KS
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
66205
CY2023Q1 dei City Area Code
CityAreaCode
(913)
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
942-2300
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11704142 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1738760 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5356276 usd
CY2023Q1 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
31953 usd
CY2022Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
234432 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1982692 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2278944 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
3753405 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
7869652 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2841293 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2904787 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
568259 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
630618 usd
CY2023Q1 us-gaap Assets
Assets
7162957 usd
CY2022Q4 us-gaap Assets
Assets
11405057 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
599033 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
762357 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
699182 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
894635 usd
CY2023Q1 us-gaap Notes Payable Current
NotesPayableCurrent
5000000 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
5000000 usd
CY2023Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
16300 usd
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
16053 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
344026 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
339755 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
6658541 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7012800 usd
CY2023Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
17320 usd
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
21487 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
405482 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
488748 usd
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
422802 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
510235 usd
CY2023Q1 us-gaap Liabilities
Liabilities
7081343 usd
CY2022Q4 us-gaap Liabilities
Liabilities
7523035 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11309412 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11309412 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11309412 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11309412 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
1131 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1131 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
73493866 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
73289387 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-73413383 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-69408496 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
81614 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3882022 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7162957 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11405057 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2128616 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2762284 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1721379 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2247060 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3849995 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5009344 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-154892 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5833 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4004887 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5003511 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4004887 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5003511 usd
CY2022Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-2948 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4004887 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5006459 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11309412 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11309412 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
20843542 usd
CY2022Q1 CING Aoci Unrealized Losses On Available For Sale Investments
AociUnrealizedLossesOnAvailableForSaleInvestments
-2948 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
181518 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5003511 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
16018601 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3882022 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3882022 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
204479 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4004887 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
81614 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
81614 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4004887 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5003511 usd
CY2023Q1 us-gaap Depreciation
Depreciation
100629 usd
CY2022Q1 us-gaap Depreciation
Depreciation
101429 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
204479 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
181518 usd
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2948 usd
CY2023Q1 us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
-202479 usd
CY2022Q1 us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
-38877 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-296252 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-391216 usd
CY2023Q1 CING Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-62359 usd
CY2022Q1 CING Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-53889 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-358777 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
446374 usd
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
4271 usd
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
7668 usd
CY2023Q1 CING Increase Decrease In Longterm Portion Of Operating Lease Liability
IncreaseDecreaseInLongtermPortionOfOperatingLeaseLiability
-83266 usd
CY2022Q1 CING Increase Decrease In Longterm Portion Of Operating Lease Liability
IncreaseDecreaseInLongtermPortionOfOperatingLeaseLiability
-78995 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3576461 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3864483 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
37135 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10400 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-37135 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10400 usd
CY2023Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
3920 usd
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
3682 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3920 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3682 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3617516 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3878565 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5356276 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16492745 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1738760 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12614180 usd
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
10400 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
555 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
793 usd
CY2021Q4 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
20400000 usd
CY2022Q3 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
5000000.0 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.03662 pure
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_z6Qk4tAeEkS4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zBLmiaNbveMk">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash equivalent deposits, which at various times throughout the fiscal year exceeded the amounts insured by the Federal Deposit Insurance Corporation limit of $<span id="xdx_901_eus-gaap--TimeDepositsAtOrAboveFDICInsuranceLimit_iI_c20230331_zaQ6KKpNf5Ye" title="Federal deposit insurance corporation limit">250,000</span> (without regard to reconciling items). Management monitors the soundness of these financial institutions and does not believe the Company is subject to any material credit risk relative to the uninsured portion of the deposits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 us-gaap Time Deposits At Or Above Fdic Insurance Limit
TimeDepositsAtOrAboveFDICInsuranceLimit
250000 usd
CY2023Q1 CING Prepaid Research And Development
PrepaidResearchAndDevelopment
901601 usd
CY2022Q4 CING Prepaid Research And Development
PrepaidResearchAndDevelopment
1377391 usd
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
569155 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
472152 usd
CY2023Q1 CING Prepaid Active Pharmaceutical Ingredients
PrepaidActivePharmaceuticalIngredients
209156 usd
CY2022Q4 CING Prepaid Active Pharmaceutical Ingredients
PrepaidActivePharmaceuticalIngredients
209156 usd
CY2023Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
146456 usd
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
100339 usd
CY2023Q1 CING Prepaid Professional Fees
PrepaidProfessionalFees
20775 usd
CY2022Q4 CING Prepaid Professional Fees
PrepaidProfessionalFees
61524 usd
CY2023Q1 CING Prepaid Dues And Subscriptions
PrepaidDuesAndSubscriptions
73976 usd
CY2022Q4 CING Prepaid Dues And Subscriptions
PrepaidDuesAndSubscriptions
37684 usd
CY2023Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
61573 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
20698 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1982692 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2278944 usd
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5001989 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4964853 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2160696 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2060066 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2841293 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2904787 usd
CY2023Q1 us-gaap Depreciation
Depreciation
100629 usd
CY2023Q1 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
89517 usd
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
479839 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
292339 usd
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
15000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
314446 usd
CY2023Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
175625 usd
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
175625 usd
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
28718 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
112225 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
699182 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
894635 usd
CY2023Q1 us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<p id="xdx_806_eus-gaap--LossContingencyDisclosures_zy7aMCb47rQl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(6)</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_822_zTglblEGzKji">Contingencies</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may, from time to time, be subject to legal proceedings and claims arising in the ordinary course of business and otherwise. A substantial legal liability against us could have an adverse effect on our business, financial condition and results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records legal costs associated with loss contingencies as incurred and establishes reserves when those matters present material loss contingencies that management determines to be both probable and reasonably estimable in accordance with ASC 450, <i>Contingencies. </i>If a range of loss is estimated, and some amount within that range appears to be a better estimate than any other amount within that range, then that amount is accrued. If no amount within the range can be identified as a better estimate than any other amount, we accrue the minimum amount in the range. These amounts are not reduced by amounts that may be recovered under insurance or claims against third parties, but undiscounted receivables from insurers or other third parties may be accrued separately if recovery is considered probable. Management’s judgment is required related to loss contingencies because the outcomes are difficult to predict, and the ultimate resolution may differ from our current analysis. The Company revises accruals in light of new information. While it is not possible to predict the outcome of loss contingencies with certainty, management is of the opinion that adequate provision for potential losses associated with any such matters has been made in the financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 us-gaap Interest Expense
InterestExpense
187500 usd
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11309412 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11309412 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11309412 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11309412 shares
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
204479 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
181518 usd
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.01540 pure
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.0113 pure
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.0112 pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
0.99
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
1.97
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 usd
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-841026 usd
CY2022Q1 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1039582 usd
CY2023Q1 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-221470 usd
CY2022Q1 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-273757 usd
CY2023Q1 CING Income Tax Reconciliation Permanent Difference
IncomeTaxReconciliationPermanentDifference
3669 usd
CY2022Q1 CING Income Tax Reconciliation Permanent Difference
IncomeTaxReconciliationPermanentDifference
5665 usd
CY2023Q1 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1090836 usd
CY2022Q1 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1361886 usd
CY2023Q1 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-32009 usd
CY2022Q1 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-54212 usd
CY2023Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
6989779 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
5580595 usd
CY2023Q1 CING Deferred Tax Assets In Research And Development Costs Current
DeferredTaxAssetsInResearchAndDevelopmentCostsCurrent
450718 usd
CY2022Q4 CING Deferred Tax Assets In Research And Development Costs Current
DeferredTaxAssetsInResearchAndDevelopmentCostsCurrent
343087 usd
CY2023Q1 CING Deferred Tax Assets Other Current
DeferredTaxAssetsOtherCurrent
59018 usd
CY2022Q4 CING Deferred Tax Assets Other Current
DeferredTaxAssetsOtherCurrent
59018 usd
CY2023Q1 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4250020 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3381215 usd
CY2023Q1 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2098416 usd
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1762716 usd
CY2023Q1 CING Deferred Tax Assets Unvested Stock Options Non Current
DeferredTaxAssetsUnvestedStockOptionsNonCurrent
283259 usd
CY2022Q4 CING Deferred Tax Assets Unvested Stock Options Non Current
DeferredTaxAssetsUnvestedStockOptionsNonCurrent
204380 usd
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
92417 usd
CY2023Q1 CING Deferred Tax Assets Rightofuse Assets
DeferredTaxAssetsRightofuseAssets
58012 usd
CY2022Q4 CING Deferred Tax Assets Rightofuse Assets
DeferredTaxAssetsRightofuseAssets
63563 usd
CY2023Q1 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
7288960 usd
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
5906396 usd
CY2023Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
6989779 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
5580595 usd
CY2023Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
299181 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
325801 usd
CY2023Q1 CING Deferred Tax Liabilities Accrual To Cash Current
DeferredTaxLiabilitiesAccrualToCashCurrent
11228 usd
CY2022Q4 CING Deferred Tax Liabilities Accrual To Cash Current
DeferredTaxLiabilitiesAccrualToCashCurrent
11228 usd
CY2023Q1 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
287953 usd
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
314573 usd
CY2023Q1 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
299181 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
325801 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4004887 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5003511 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11309412 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11309412 shares
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6239902 shares
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5866282 shares
CY2023Q1 us-gaap Interest Expense
InterestExpense
187500 usd
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
479839 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
292339 usd

Files In Submission

Name View Source Status
cing-20230331_lab.xml Edgar Link unprocessable
0001493152-23-016183-index-headers.html Edgar Link pending
0001493152-23-016183-index.html Edgar Link pending
0001493152-23-016183.txt Edgar Link pending
0001493152-23-016183-xbrl.zip Edgar Link pending
cing-20230331.xsd Edgar Link pending
ex10-5.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
cing-20230331_pre.xml Edgar Link unprocessable
cing-20230331_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cing-20230331_def.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending